Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric M Horwitz

Showing results (21-30 of 192) with videos related to

Pageof 20
Sort By:
Cancer|May 1, 2012
Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification methodNicholas G Zaorsky, Tianyu Li, Karthik Devarajan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2004
A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapyDerek B Chism, Alexandra L Hanlon, Eric M Horwitz, et al.
JAMA|November 4, 2004
Androgen suppression plus radiation therapy for prostate cancerEric M Horwitz, Steven J Feigenberg, Alan Pollack, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?Khanh H Nguyen, Eric M Horwitz, Alexandra L Hanlon, et al.
The Journal of Urology|February 10, 2004
Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search databaseMark K Buyyounouski, Eric M Horwitz, Alexandra L Hanlon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 25, 2014
Does family history of prostate cancer affect outcomes following radiotherapy?Hilary Bagshaw, Karen Ruth, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratioAlan E Nahum, Benjamin Movsas, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2005
Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivationMark K Buyyounouski, Alexandra L Hanlon, Eric M Horwitz, et al.
Cancer|January 28, 2004
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancerRojymon Jacob, Alexandra L Hanlon, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
Biochemical failure rates in prostate cancer patients predicted to have biologically insignificant tumors treated with three-dimensional conformal radiation therapyNoel M Kramer, Alexandra L Hanlon, Eric M Horwitz, et al.
Pageof 20

Showing results (21-30 of 192) with videos related to

Sort By:
Pageof 20
Cancer|May 1, 2012
Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification methodNicholas G Zaorsky, Tianyu Li, Karthik Devarajan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2004
A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapyDerek B Chism, Alexandra L Hanlon, Eric M Horwitz, et al.
JAMA|November 4, 2004
Androgen suppression plus radiation therapy for prostate cancerEric M Horwitz, Steven J Feigenberg, Alan Pollack, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?Khanh H Nguyen, Eric M Horwitz, Alexandra L Hanlon, et al.
The Journal of Urology|February 10, 2004
Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search databaseMark K Buyyounouski, Eric M Horwitz, Alexandra L Hanlon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 25, 2014
Does family history of prostate cancer affect outcomes following radiotherapy?Hilary Bagshaw, Karen Ruth, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratioAlan E Nahum, Benjamin Movsas, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2005
Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivationMark K Buyyounouski, Alexandra L Hanlon, Eric M Horwitz, et al.
Cancer|January 28, 2004
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancerRojymon Jacob, Alexandra L Hanlon, Eric M Horwitz, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
Biochemical failure rates in prostate cancer patients predicted to have biologically insignificant tumors treated with three-dimensional conformal radiation therapyNoel M Kramer, Alexandra L Hanlon, Eric M Horwitz, et al.
Pageof 20